CAI Caris Life Sciences, Inc.

“the previously reported material weakness in our internal control over financial reporting pertaining to a lack of sufficient qualified accounting resources, including those necessary to account for and disclose accounting transactions that require complex calculations or thorough evaluation of the accounting literature”

“have concluded that these disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2026 due to the previously reported material weakness in our internal control over financial reporting”

“our estimates regarding our expenses, future revenue, and capital requirements; and remediating the material weakness in our internal control over financial reporting.”